Abstract: A method for producing a high sapogenin content composition, including: allowing a strong acid aqueous solution having a concentration of 0.01 mol/L to 4 mol/L to act on a saponin-containing plant, so as to perform hydrolysis treatment; neutralizing a liquid obtained by the hydrolysis treatment; filtering the liquid so as to obtain a residue; and drying the residue.

Abstract: A power feeding system includes: a power feeder including a mount, a primary coil, a moving means, a query output means outputting a query, a receiving means receiving notification information, a primary coil direct-current driving control means controlling the primary coil to be driven with a direct current, a query control means allowing the query output means to output a query, and a primary coil alternating-current driving control means controlling the primary coil to be driven with an alternating current; and a power-receiving equipment including a secondary coil, a sensing means disposed at a position where the sensing means can sense the query, a secondary coil direct-current driving control means controlling the secondary coil to be driven with a direct current, a notification information output means, and a secondary coil alternating-current driving control means controlling the secondary coil so that electromotive force induced by the primary coil is exerted.

Abstract: A novel oligonucleotide useful as an NF-?B decoy having a higher binding ability to NF-?B than known NF-?B decoy as well as the medical uses thereof, is disclosed. The oligonucleotide of the invention has a base sequence having a consensus sequence and specific 5?-flanking and 3?-flanking sequences ligated to both ends of the consensus sequence, respectively. The NF-?B decoy is constituted by an oligonucleotide which is the above-described oligonucleotide of the invention and which is substantially double-stranded wherein the strands are complementary to each other.

Abstract: A novel cell suited for mass production of Hemagglutinating Virus of Japan (HVJ), a method for obtaining the cell and use of the cell are disclosed. The human cell is originated from a transformed human kidney cell line, the doubling time thereof in logarithmic growth phase in suspension culture in a serum-free medium is not more than 40 hours, the cell has a freeze-recovery property, the maximum density of viable cells in suspension culture is not less than 106 cells/mL, and HVJ can grow in the cell. The method for obtaining the human cell comprises the steps of suspension-culturing a human transformed kidney cell line in a serum-free medium, and cloning the grown cells; and selecting, from the cloned cells, a cell whose doubling time in logarithmic growth phase in suspension culture in a serum-free medium is not more than 40 hours, which has a freeze-recovery property, whose maximum density of viable cells in suspension culture is not less than 106 cells/mL, in which HVJ can grow.